For people who have had a heart attack, taking a high dose of atorvastatin (up to 40mg/day) has no added benefit over a moderate dose (10mg/day) a study has shown.
In a two year clinical trial involving more than 1300 patients with acute coronary syndromes (ACS), cardiologists from the Second Xiangya Hospital of Central South University, Changsha, found that the dose of statin had no impact on the primary end points of cardiac death, non-fatal acute myocardial infarction, revascularization, ischaemic stroke and unstable angina or severe heart failure requiring emergency hospitalization. The patients' lipid levels were low initially (mean LDL cholesterol level of 2.7mmol/L) and declined by 20% in the moderate dose statin group and 27% in the intensive statin group, respectively.
"For ACS patients with a relatively low baseline LDL cholesterol level who received optimized current medication and interventional therapy, the incremental LDL cholesterol reduction of 6.4% achieved by double-dose statin did not bring significant clinical effectiveness," the researchers concluded.
The findings are published in Atherosclerosis.